Purpose: Recent studies have identified microRNA-944 (miR-944) as a cancer-related miRNA, but its expression and precise functions in hepatocellular carcinoma (HCC) remain unknown. Patients and methods: miR-944 expression in HCC tissues and cell lines were detected by RT-qPCR. A series of functional assays were utilized to examine the influence of miR-944 on the malignant phenotypes of HCC cells in vitro and in vivo. More importantly, the associated mechanisms underlying the activity of miR-944 in HCC cells were investigated using bioinformatics, luciferase reporter assays, RT-qPCR, and western blot analysis. Results: In this study, we report for the first time, a significant downregulation of miR-944 in HCC tissues and cell lines and the correlation between its downregulation and malignant clinical parameters, including Edmondson-Steiner grade, TNM stage, and venous infiltration. Low miR-944 expression predicted poorer overall survival rate and disease-free survival rate in patients with HCC. Functionally, exogenous miR-944 expression attenuated cell proliferation, clone formation, metastasis, and epithelial-mesenchymal transition and increased apoptosis in HCC, whereas miR-944 knockdown produced the opposite results. In addition, ectopic miR-944 expression hindered HCC tumor growth in vivo. Mechanistically, insulinlike growth factor 1 receptor (IGF-1R) was demonstrated to be the direct target gene of miR-944 in HCC cells. Furthermore, the expression level of miR-944 was inversely correlated with IGF-1R expression in HCC tissues. Rescue experiments showed that IGF-1R was at least partially responsible for the effects of miR-944 on the malignant phenotypes of HCC cells. In addition, the PI3K/Akt pathway was notably deactivated, both in vitro and in vivo, upon miR-944 upregulation. Conclusion: This study provides the first evidence that miR-944 directly targets IGF-1R and inhibits the aggressiveness of HCC, in vitro and in vivo, by decreasing PI3K/Akt signaling. Hence, targeting miR-944 may open a new avenue for the treatment of patients with HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies and ranks as the third leading cause of cancer-associated deaths globally. 1 The morbidity of HCC is continuing to grow and causes a heavy healthcare-related economic burden in developing countries, including China. 2 In recent years, there have been remarkable developments in therapeutic strategies to combat this disease, including surgical resection, radiofrequency ablation, liver transplantation, and radiochemotherapy, but the clinical outcomes of patients with HCC are still dissatisfying due to frequent intrahepatic spread and extrahepatic metastasis. 3 The other major reason for the poor prognosis of patients with HCC is that the etiology and exact mechanisms underlying hepatocarcinogenesis are not fully understood. 4, 5 Therefore, uncovering the complex molecular mechanisms responsible for the pathogenesis of HCC is urgently needed to enable the discovery of novel biomarkers for diagnosis and prognosis and to identify promising therapeutic targets for patients with HCC. microRNAs (miRNAs) are single-stranded, non-coding, short RNA molecules measuring approximately 17-23 nucleotides in length. 6 miRNAs are able to post-transcriptionally modulate gene expression by promoting mRNA degradation and inducing translational inhibition by directly binding to complementary sites within the 3′-untranslated regions (3′-UTRs) of their target genes. 7 More than 1,500 mature miRNAs have been identified in the human genome and these miRNAs regulate approximately one third of all human protein-coding genes. 8 Increasing evidence indicates that a variety of miRNAs are aberrantly expressed in HCC. For example, miR-34a, 9 miR-506, 10 and miR-645 11 are downregulated in HCC, whereas miR-197, 12 miR-552, 13 and miR-650 14 are expressed at high levels in HCC. The dysregulated miRNAs exert their functions as oncogenes or tumor suppressors and play crucial roles in the initiation and progression of HCC. [15] [16] [17] Therefore, therapies that target miRNAs may be attractive strategies for HCC treatment.
Recently, miR-944 has been reported to serve both tumorsuppressing 18, 19 and tumor-promoting [20] [21] [22] roles, depending on the type of human malignancy. These conflicting observations indicate that the role of miR-944 in tumorigenesis is tissue-specific. However, details of the expression, clinical significance, and precise functions of miR-944 in HCC are not yet known. Hence, we attempted to determine the expression pattern and clinical value of miR-944 in HCC. The detailed roles of miR-944 in the malignant development of HCC and the associated mechanisms were also examined.
Material and methods

Patients and tissue specimens
HCC and adjacent normal tissues (ANTs) were obtained from 61 patients with HCC who underwent surgical resection at The Second Hospital of Jilin University. None of these patients received radiofrequency ablation, radiotherapy, or chemotherapy before surgery. Tumor stage was classified according to the TNM classification system advocated by the International Union against Cancer and was followed up until June 2018. Tissues were collected from the 61 patients, frozen in liquid nitrogen, and then stored at −80°C for further analyses. The present study was approved by the Ethics Committee of The Second Hospital of Jilin University and was performed in accordance with the ethical standards of the Declaration of Helsinki. In addition, written informed consent was provided by all patients.
Cell culture
The immortalized human hepatic cell line L02, and a panel of HCC cell lines (Hep3B, Bel-7402, SMMC-7721, Huh7, and SK-HEP-1) were purchased from the Shanghai Cell Bank of the Chinese Academy of Science (Shanghai, China). All cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in an incubator containing 5% CO 2 .
Cell transfection assays miR-944 mimics, a miR-944 inhibitor, negative control miRNA mimics (miR-NC), and a negative control miRNA inhibitor (NC inhibitor) were provided by Shanghai GenePharma Co., Ltd. (Shanghai, China). A small interfering RNA (siRNA) used to knockdown IGF-1R expression (si-IGF-1R) and a control siRNA (si-ctrl) were chemically synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China).
The pcDNA3.1-IGF-1R (pc-IGF-1R) plasmid was employed to increase the expression of IGF-1R and an empty pcDNA3.1 plasmid was used as a control. Plasmids were chemically synthesized by the Chinese Academy of Sciences (Changchun, China).
For transfection, cells were plated into 6-well plates. Transfection was performed when the cells had grown to approximately 60-70% density. Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific) was used for transfections and assays were performed according to the product specifications. After 8 h of culture, culture medium was replaced with fresh DMEM containing 10% FBS.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
TRIzol reagent (Invitrogen) was used to extract total RNA, following the manufacturer's recommendations. The concentration of isolated RNA was evaluated using a Nanodrop-ND -1000 (Thermo Fisher Scientific, Inc.). To quantify miRNA expression, cDNA was prepared from total RNA using the miScript Reverse Transcription Kit (Qiagen GmbH, Hilden, Germany). Thereafter, the amplification of cDNA was performed using the miScript SYBR Green PCR Kit (Qiagen GmbH). Alternatively, reverse transcription was performed using the TaqMan RT reagent (Applied Biosystems; Thermo Fisher Scientific, Inc.), followed by qPCR using the SYBR®-Green PCR Master Mix Kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). U6 snRNA and GAPDH were used as controls for quantitating miR-944 and IGF-1R expression, respectively. Each assay was performed in triplicate and relative gene expression was calculated using the 2 −ΔΔCq method.
Cell Counting Kit-8 (CCK-8) and clone formation assays
For CCK-8 assays, transfected cells were collected and inoculated into 96-well plates (2,000 cells/well). Each group had three repeated wells. After 0, 1, 2, or 3 d, 10 μL of CCK-8 reagent (Beyotime Institute of Biotechnology, Inc., Shanghai, China) was added to each well. Cells were then incubated at 37°C for 2 h and the absorbance at 450 nm (A450) was determined using a Spectramax M5 microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA). For colony formation assays, 1,000 cells were seeded into 6-well plates. After 14 d of culture, cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of clones (defined as ≥50 cells/clone) was counted using an inverted light microscope (IX83; Olympus Corporation, Tokyo, Japan).
Apoptosis assays
Apoptosis was determined using an Annexin V-Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit (Biolegend, San Diego, CA, USA). Transfected cells were detached with trypsin (Gibco) and washed twice with ice-cold PBS at 4°C. After centrifugation, cells were resuspended in 100 µL of 1X binding buffer and double-stained with 5 µL Annexin V-FITC and 5 µL propidium iodide. Following 20 min of incubation in the dark at room temperature, apoptosis rate was measured using a flow cytometer (FACScan™, BD Biosciences, Franklin Lakes, NJ, USA). 
Cell migration and invasion assays
Target prediction and luciferase reporter assays
TargetScan (http://www.targetscan.org/), miRDB (http:// mirdb.org/) and MiRanda (http://www.microrna.org) were used for target prediction.
A fragment of the IGF-1R 3′-UTR, containing the wild-type (wt) miR-944 target site, was amplified by Shanghai GenePharma Co., Ltd. The binding sequences in the 3′-UTR of IGF-1R were mutated, and the IGF-1R 3′-UTR wt and mutant (mut) fragments were inserted into the pmirGLO luciferase reporter plasmid (Promega, Madison, WI, USA). Cells were plated in triplicate in 24-well plates and allowed to settle for 12 h. The chemically synthesized luciferase reporter plasmids, along with miR-944 mimics or miR-944 inhibitor, were co-transected into cells, according to the Lipofectamine™ 2000 reagent protocol. Luciferase activity was detected 48 h post-transfection using a Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase activity was used for normalization.
Protein extraction and western blotting analysis
Homogenized tissues or cells were lysed with an active protein extraction kit (KGP1050; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) containing protease inhibitor and protein was quantified using a BCA Protein Assay Kit (Beyotime Institute of Biotechnology). Equal amounts of protein were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gels and then transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% nonfat powdered milk at room temperature for 2 h and were subsequently incubated overnight at 4°C with the appropriate primary antibodies. After washing thrice with TBS containing 0.1% Tween-20 (TBST), membranes were incubated for 2 h at room temperature with a horseradish peroxidase-conjugated goat anti-mouse (catalog no. ab205719; Abcam, Cambridge, MA, USA) or goat anti-rabbit (catalog no. ab205718; Abcam) secondary antibody at a 1:5,000 dilution. They were then extensively washed with TBST. Protein bands were detected using an Enhanced Chemiluminescence Detection System (Pierce; Thermo Fisher Scientific, Inc.).
The primary antibodies used for western blotting analysis were as follows: anti-E-cadherin (cat. no. ab1416), anti-N-cadherin (cat. no. ab76011), anti-vimentin (cat. no. ab92547), anti-p-PI3K (cat. no. ab182651), and anti-PI3K (cat. no. ab191606) were purchased from Abcam and anti-IGF-1R (cat. no. sc-81464), anti-p-Akt (cat. no. sc-81433), anti-Akt (cat. no. sc-81464), and anti-GAPDH (cat. no. sc-365062) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA).
Statistical analysis
Results were expressed as mean ± standard deviation from at least three separate experiments. A Chi-square test was applied to assess the relationship between miR-944 expression and clinicopathological parameters in patients with HCC. A log-rank test was used to examine the association between miR-944 expression and overall survival and disease-free survival of patients with HCC. The correlation between miR-944 and IGF-1R mRNA levels in HCC tissues was determined by Spearman's correlation analysis. Differences between two or multiple groups were evaluated by two-tailed Student's t-test or one-way analysis of variance (ANOVA), respectively. The StudentNewman-Keuls test was used as the post hoc test after ANOVA. SPSS 19.0 software (IBM Corporation, Armonk, NY, USA) was used for all statistical analyses, and a P-value <0.05 was defined as statistically significant.
Results
miR-944 is downregulated in HCC and indicates poor prognosis for patients with HCC
To investigate the relationship between miR-944 and HCC, RT-qPCR was employed to measure miR-944 expression in 61 pairs of HCC tissues and ANTs. The data showed that miR-944 expression was significantly decreased in HCC tissues compared with ANTs ( Figure 1A , P<0.05). In addition, we determined the expression difference of miR-944 in five HCC cell lines (Hep3B, Bel-7402, SMMC-7721, Huh7, SK-HEP-1) and one immortalized human hepatic cell line (L02). Consistent with the trend in tissue specimens, miR-944 expression was significantly lower in all five HCC cell lines than that in L02 cells ( Figure 1B , P<0.05).
We then explored the clinical utility of miR-944 in patients with HCC. The patients with HCC were categorized into two subgroups (low or high miR-944 expression groups) based on the median value of miR-944 levels in HCC tissues. As shown in Table 1 , low miR-944 expression was significantly correlated with Edmondson-Steiner grade (P=0.007), TNM stage (P=0.013), and venous infiltration (P=0.001) in patients with HCC, suggesting that tumors with decreased miR-944 levels may be more aggressive. Furthermore, patients with HCC who had lower miR-944 expression had a poorer overall survival rate ( Figure 1C , P = 0.038) and disease-free survival rate ( Figure 1D , P = 0.034). These observations indicated that miR-944 may be a promising biomarker for HCC diagnosis and prognosis.
miR-944 suppresses the growth of HCC cells in vitro
Since miR-944 was significantly downregulated in HCC, we speculated that miR-944 may have a crucial role in the aggressiveness of HCC cells. To evaluate this hypothesis, Hep3B and Huh7 cell lines, which exhibited relatively low and relatively high miR-944 levels, respectively, were chosen for subsequent functional experiments. Hep3B cells were transfected with miR-944 mimics, while a miR-944 inhibitor was introduced into Huh7 cells. The efficiency of transfection was confirmed by RT-qPCR. miR-944 was overexpressed in Hep3B cells and silenced in Huh7 cells (Figure 2A, P<0.05 ). CCK-8 and clone formation assays demonstrated that the upregulation of miR-944 suppressed the proliferative and clone-formation capacities of Hep3B cells, whereas inhibition of miR-944 promoted these abilities ( Figure 2B and C, P<0.05). Furthermore, the influence of miR-944 on the apoptosis of HCC cells was examined. Apoptosis assay results showed that transfection with miR-944 mimics increased the percentage of apoptotic Hep3B cells, whereas transfection with a miR-944 inhibitor decreased the percentage of apoptotic Huh7 cells ( Figure 2D , P<0.05). Altogether, miR-944 exerted an inhibitory effect on the growth of HCC cells in vitro.
miR-944 restricts the metastasis and epithelial-mesenchymal transition (EMT) of HCC cells in vitro
Cell migration and invasion assays were performed to explore the precise roles of miR-944 in the metastasis of HCC cells. Results showed that the migratory and invasive abilities of HCC cells were notably attenuated by exogenous miR-944 expression ( Figure 3A , P<0.05), but significantly increased by miR-944 knockdown ( Figure 3B , P<0.05). Tumor metastasis is a complex process that is regulated by several cellular processes, including EMT. Hence, western blotting analysis was performed to determine the expression levels of EMT markers in Hep3B and Huh7 cells after transfection with miR-944 mimics or a miR-944 inhibitor, respectively. As indicated in Figure 3C , miR-944 overexpression markedly increased the expression of the epithelial marker, E-cadherin, and suppressed the expression of the mesenchymal markers, N-cadherin and vimentin, in Hep3B cells. In contrast, the protein levels of E-cadherin were downregulated, while N-cadherin and vimentin levels were upregulated in Huh7 cells upon miR-944 silencing ( Figure 3C ). These results implied that miR-944 decreased metastasis and EMT in HCC cells in vitro. 
IGF-1R is a downstream target of miR-944 in HCC cells
To elucidate the potential effectors of miR-944 in the progression of HCC, bioinformatics tools were used to predict the putative target of miR-944. The 3′-UTR of IGF-1R contains two major miR-944 binding sites ( Figure 4A ). IGF-1R, a well-known oncogene, has been reported to be a regulator of hepatocarcinogenesis.
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Therefore, IGF-1R was chosen for further validation. Luciferase reporter assays were performed to test whether miR-944 directly targets the 3′-UTR of IGF-1R in HCC cells. Ectopic miR-944 expression resulted in a significant decrease in the luciferase activity of the plasmid harboring the wt IGF-1R 3′-UTR (1 and 2) in Hep3B cells, whereas silencing miR-944 expression increased the luciferase activity of the wt IGF-1R 3′-UTR (1 and 2) in Huh7 cells (P<0.05). However, the luciferase activity of the mutant IGF-1R 3′-UTR (1 and 2) was unaffected by either miR-944 induction or knockdown ( Figure 4B ). To further explore whether IGF-1R was a bona fide downstream target of miR-944, RT-qPCR and western blotting were used to determine how changes in miR-944 expression affected IGF-1R expression in HCC cells. The mRNA and protein levels of IGF-1R were suppressed in Hep3B cells after miR-944 overexpression, whereas downregulation of miR-944 led to the opposite results in Huh7 cells ( Figure 4C and D, P<0.05). These results suggest that IGF-1R is a direct target gene of miR-944 in HCC cells. 
Mir-944 is inversely correlated with IGF-1R expression in HCC tissues
To further investigate the relationship between miR-944 and IGF-1R in HCC, we investigated IGF-1R mRNA and protein expression in HCC tissues and ANTs. IGF-1R mRNA was expressed at high levels in HCC tissues as compared to the ANTs ( Figure 5A , P<0.05). As all patients with HCC could be divided into two subgroups, low or high miR-944 expression groups, we next explored the relationship between miR-944 expression and IGF-1R expression in HCC tissues. The mRNA and protein levels of IGF-1R were significantly higher in the low miR-944 expression group compared to the high miR-944 expression group ( Figure 5B and C, P<0.05). Furthermore, an inverse association between miR-944 and IGF-1R mRNA expression levels was demonstrated by Spearman's correlation analysis ( Figure 5D ; R 2 = 0.3402, P < 0.0001). These results further suggest that IGF-1R is a downstream target of miR-944 in HCC cells.
IGF-1R mediates the functional roles of miR-944 in HCC cells
Rescue experiments were performed to further clarify whether IGF-1R was essential for the effects of miR-944 in HCC cells. IGF-1R expression was restored in miR-944 mimics-transfected Hep3B cells after co-transfection with the IGF-1R-overexpressing plasmid, pcDNA3.1-IGF-1R (pc-IGF-1R), while IGF-1R siRNA (si-IGF-1R) knocked down IGF-1R expression in miR-944 inhibitor-transfected Huh7 cells ( Figure 6A , P<0.05). Reintroduction of IGF-1R expression partially counteracted the tumor-suppressing effects of miR-944 mimics on the proliferation ( Figure 6B ; P < 0.05), clone formation ( Figure 6C ; P < 0.05), apoptosis ( Figure 6D ; P < 0.05), migration ( Figure 7A ; P < 0.05), invasion ( Figure 7B ; P < 0.05), and EMT ( Figure 7C ) of Hep3B cells. Meanwhile, the tumor-promoting activity of miR-944 inhibition on the malignant phenotypes of Huh7 cells was attenuated by co-transfection with si-IGF-1R. These results suggest that miR-944 regulates the malignant progression of HCC, at least partially, by regulating IGF-1R expression. 
miR-944 suppresses HCC tumor growth in vivo by regulating the IGF-1R/PI3K/Akt pathway
To examine the effect of miR-944 on tumor growth in vivo, Hep3B cells transfected with miR-944 mimics were injected into nude mice. miR-NC-transfected cells were used as controls. Tumor growth ( Figure 9A and B, P<0.05) and weight ( Figure 9C , P<0.05) were significantly impaired in the miR-944 mimics group. To further investigate whether the inhibitory role in HCC tumor growth in vivo was due to miR-944 overexpression, RT-qPCR analysis was performed to quantify miR-944 expression in tumor xenografts. Significantly higher miR-944 expression was observed in tumor xenografts derived from miR-944 mimics-treated nude mice than in those derived from miR-NC-treated mice ( Figure 9D , P<0.05). In addition, the protein levels of IGF-1R, p-PI3K, and p-Akt decreased in the tumor xenografts from the miR-944 mimics group ( Figure 9E ). These results indicated that miR-944 hindered HCC tumor growth in vivo, at least in part, by inhibiting IGF-1R and the activation of the PI3K/Akt pathway. 
Discussion
Dysregulated miRNAs are frequently reported in HCC and this has been shown to be important in regulating the pathogenesis and progression of the disease. 15, 32, 33 More importantly, abnormally expressed miRNAs are suggested to be promising indicators for diagnosis and prognosis, as well as therapeutic targets for patients with HCC. 34 Therefore, an in-depth understanding of the relevant mechanisms whereby miRNAs affect HCC is urgent and important. However, studies investigating the expression patterns and precise roles of miR-944 in HCC are still quite limited. Therefore, in this study, we investigated miR-944 expression in HCC and explored the detailed roles of miR-944 in the malignant progression of HCC. The molecular mechanisms related to the tumor suppressor activity of miR-944 in HCC were also examined. To the best of our knowledge, this is the first study demonstrating that miR-944 exerts anticancer effects on HCC cells by specifically targeting IGF-1R and deactivating the PI3K/ Akt signaling pathway. miR-944 is expressed at low levels in colorectal cancer, and low miR-944 expression is significantly correlated with the tumor invasion stage, lymph node metastasis, distant metastasis, and TNM stage. Colorectal cancer patients with decreased miR-944 expression have shorter 5-year overall and progression-free survival times than those with high miR-944 expression.
18 miR-944 is also downregulated in gastric 35 and non-small cell lung 19 cancers. In contrast, miR-944 expression is upregulated in endometrial, 20 cervical, 21 HCC. Survival analysis has shown that patients with HCC who display high IGF-1R expression have poorer overall and disease-free survival than those with low IGF-1R
expression. In addition, multivariate analysis has identified high IGF-1R expression as an independent prognostic marker of poor survival in patients with HCC. 23 IGF-1R is able to activate multiple components of the PI3K/Akt pathway and it contributes to the aggressive characteristics of HCC, including cell proliferation, apoptosis, migration, invasion, and chemotherapy resistance. [24] [25] [26] [27] [28] [29] In our current study, miR-944 was shown to be a negative regulator of IGF-1R and could inhibit the malignant phenotypes of HCC in vitro and in vivo by decreasing PI3K/Akt signaling. These results suggest that miR-944 restoration-mediated silencing of IGF-1R expression may be an effective approach to treat patients with HCC. 
Conclusion
In summary, we determined the clinical and biological roles of the miR-944/IGF-1R axis in HCC and identified the PI3K/ Akt signaling pathway as the downstream effector. The miR-944/IGF-1R axis suppressed the progression and development of HCC and the PI3K/Akt pathway was notably deactivated in this process. These observations suggest that miR-944 is a potential prognostic indicator and may provide alternative therapeutic opportunities for patients with HCC. However, we did not explore whether the morphological evidence for EMT-like characteristics in HCC cells could be affected by miR-944. It was a limitation of the present study that may be resolved in future investigations.
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